DATA GRAPHICS | Data Byte
Upcoming decisions include BridgeBio’s ATTR cardiomyopathy drug, PTC’s gene therapy, and Autolus’ CD19 CAR T
By Gunjan Ohri, Data Content Analyst
October 31, 2024 12:18 AM UTC
Among the seven disclosed PDUFA dates coming up in November is a decision that could see BridgeBio enter the market for TTR amyloidosis with cardiomyopathy ahead of Alnylam.
BridgeBio Pharma Inc. (NASDAQ:BBIO) is expecting a decision by the end of the month on its application for acoramidis, a small molecule TTR stabilizer, to treat ATTR with cardiomyopathy (ATTR-CM)…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654021/seven-pdufa-dates-on-fda-s-november-calendar